Novel biomarkers including midregional pro-adrenomedullin, midkine, and pentraxin 3 offer potential for early subclinical diagnosis and future therapeutic targeting of atherosclerotic lesions.
The atherosclerotic vascular disease is a cardiovascular continuum in which the main role is attributed to atherosclerosis, from its appearance to its associated complications. The increasing prevalence of cardiovascular risk factors, population ageing, and burden on both the economy and the healthcare system have led to the development of new diagnostic and therapeutic strategies in the field. The better understanding or discovery of new pathophysiological mechanisms and molecules modulating various signaling pathways involved in atherosclerosis have led to the development of potential new biomarkers, with key role in early, subclinical diagnosis. The evolution of technological processes in medicine has shifted the attention of researchers from the profiling of classical risk factors to the identification of new biomarkers such as midregional pro-adrenomedullin, midkine, stromelysin-2, pentraxin 3, inflammasomes, or endothelial cell-derived extracellular vesicles. These molecules are seen as future therapeutic targets associated with decreased morbidity and mortality through early diagnosis of atherosclerotic lesions and future research directions.
Adam et al. (Sat,) conducted a review in Atherosclerotic vascular disease. Novel biomarkers (e.g., midregional pro-adrenomedullin, midkine, stromelysin-2, pentraxin 3) was evaluated. Novel biomarkers including midregional pro-adrenomedullin, midkine, and pentraxin 3 offer potential for early subclinical diagnosis and future therapeutic targeting of atherosclerotic lesions.